How Real-World Data Is Helping Close the Rural-Urban Health Divide
Real-world analysis can provide insights into how factors largely out of rural residents’ control impact health outcomes and access to medical care.
Real-world analysis can provide insights into how factors largely out of rural residents’ control impact health outcomes and access to medical care.
How targeted outreach and heightened engagement can help companies achieve better outcomes
Meeting individuals where they are in their healthcare journey is essential for keeping lines of communication open and creating the right conditions for people to proactively seek out diabetes care.
Obesity/overweight is a significant causal factor in chronic illness and cancer. Weight loss can help people with obesity/overweight avoid and/or manage chronic illness. GLP-1s cause weight loss. So, are GLP-1s the answer to America’s obesity and chronic illness crises? Not if we overlook a key problem at the heart of both challenges: lack of access to nutritious food in the land of plenty.
The future of American healthcare hinges on the continued support and elevation of independent primary care—a cornerstone that not only enhances healthcare quality and cost controls but also ensures a healthier and more equitable future for all.
Without taking specific steps to improve trial diversity, advances in inclusive treatments will continue at a snail’s pace.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
When striving for health equity, organizations need to adopt new methods and a new mindset in order to steer clear of using SDoH as a buzzword, and instead hit the mark of health equity results.
To succeed in ACO Reach, groups need to accurately identify the social determinants of health (SDoH) barriers affecting their patient population and determine which barriers could be addressed effectively. Some technology can accurately note specific SDoH risk factors facing a given patient and offer targeted intervention recommendations based on that patient’s unique SDoH risk factors.
Automation can be a powerful tool to bring together all the pieces needed to provide optimal care that can be scattered across various systems and apps. Whether it’s to exchange patient data quickly and easily, identify communities in need of programs to address food inequity, or reduce no-shows by sending automatic reminders, using the right technology is an essential tool for achieving better patient care.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As a physician I have witnessed the dramatic impact social determinants of health (SDOH) can have on the mental health of older patients. Fortunately, there are steps every practice can take to proactively address them.
The health system will enter a new reality with the public health emergency lifted After several renewals, most expect the Covid-19 public health emergency (PHE) to be lifted in 2023, which has huge implications for health plans and members. Medicaid/CHIP enrollment has grown by 18.2 million since the onset of the pandemic in February 2020. […]
Among the takeaways from HLTH 2022 were the impact of consolidation on clinicians, behavioral health tools to help consumers manage stress and anxiety more productively, and how health tech and medtech companies are supporting remote patient monitoring and testing.
Cultural, racial and socioeconomic barriers play a role in barriers to access, from cultural hesitancy around seeking care to distrust of healthcare institutions to the stigmatizing of Medicaid beneficiaries. As a result, engaging these populations is highly complex, highly nuanced work.
A better coronary artery stent cannot help a patient who cannot afford it, does not know they need it, doesn’t have a doctor who can make a diagnosis and identify that need. To help these patients, we urgently need to look at health equity.